Որոնման արդյունքները - Yin‐Miao Chen
- Ցուցադրվում են 1 - 10 արդյունքները 10
-
1
-
2
-
3
Treatment with pasireotide LAR normalizes prolactin levels in patients with acromegaly and hyperprolactinemia: randomized, double-blind, 12-month, phase III study Annamaria Colao, Pamela U. Freda, Feng Gu, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Marcello D. Bronstein
Հրապարակվել է 2013Artigo -
4
-
5
Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II Study William J. Gradishar, Luís Meza, Bipinkumar Amin, Dvorit Samid, Todd Hill, Yin-Miao Chen, Elyse E. Lower, P. Kelly Marcom
Հրապարակվել է 2004Artigo -
6
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multic... Michael C. Sheppard, Marcello D. Bronstein, Pamela U. Freda, Omar Serri, Laura De Marinis, Luciana Ansaneli Naves, Liudmila Rozhinskaya, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Annamaria Colao
Հրապարակվել է 2014Artigo -
7
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-b... Michael C. Sheppard, Marcello D. Bronstein, Pamela U. Freda, Omar Serri, Laura De Marinis, Luciana Ansaneli Naves, Liudmila Rozhinskaya, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Annamaria Colao
Հրապարակվել է 2015Errata/Corrigenda -
8
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study Marcello D. Bronstein, Maria Fleseriu, Sebastian Neggers, Annamaria Colao, Michael C. Sheppard, Feng Gu, Chiung‐Chyi Shen, Mônica R. Gadelha, Andrew J. Farrall, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Pamela U. Freda
Հրապարակվել է 2016Artigo -
9
Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III st... Pamela U. Freda, Maria Fleseriu, der Lely Aart Jan van, Annamaria Colao, Michael C. Sheppard, Feng Gu, Chiung‐Chyi Shen, Mônica R. Gadelha, Andrew J. Farrall, Resendiz Karina Hermosillo, Matthieu Ruffin, YinMiao Chen, Marcello D. Bronstein
Հրապարակվել է 2013Artigo -
10
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial Maria Teresa Voso, Richard A. Larson, Dan Jones, Guido Marcucci, Thomas W. Prior, Jürgen Krauter, Michael Heuser, Serena Lavorgna, Josep Nomdedéu, Susan M. Geyer, Alison Walker, Andrew H. Wei, Jorge Sierra, Miguel Á. Sanz, Joseph Brandwein, Theo M. de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Sergio Amadori, Yuan Cheng, Yin-Miao Chen, Céline Pallaud, Ling Du, Alfonso Piciocchi, Gerhard Ehninger, John C. Byrd, Christian Thiede, Konstanze Döhner, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield, Francesco Lo‐Coco
Հրապարակվել է 2020Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Internal medicine
Medicine
Acromegaly
Growth hormone
Hormone
Pasireotide
Endocrinology
Pathology
Alternative medicine
Gastroenterology
Octreotide
Placebo
Somatostatin
Surgery
Adverse effect
Breast cancer
Cancer
Crossover study
Double blind
Logistic regression
Oncology
Urology
Aspiration pneumonia
Biochemistry
Biology
Bivariate analysis
Bone disease
Brush
Capecitabine
Chemotherapy